PE51399A1 - HYDRATED CRYSTALLINE FORM OF SODIUM SALT ACID (E) -4,6-DICHLORO-3- (2-OXO-1-FENILPIRROLIDIN-3-ILIDENO-METHYL) -1H-INDOL-2-CARBOXILICO - Google Patents
HYDRATED CRYSTALLINE FORM OF SODIUM SALT ACID (E) -4,6-DICHLORO-3- (2-OXO-1-FENILPIRROLIDIN-3-ILIDENO-METHYL) -1H-INDOL-2-CARBOXILICOInfo
- Publication number
- PE51399A1 PE51399A1 PE1998000149A PE00014998A PE51399A1 PE 51399 A1 PE51399 A1 PE 51399A1 PE 1998000149 A PE1998000149 A PE 1998000149A PE 00014998 A PE00014998 A PE 00014998A PE 51399 A1 PE51399 A1 PE 51399A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- ilideno
- fenilpirrolidin
- carboxilico
- indol
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- NOJNFULGOQGBKB-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C1=NC(OCC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(OCC=3N=CC(C)=CC=3)C=C2C(SC(C)(C)C)=C1CC(C)(C)C([O-])=O NOJNFULGOQGBKB-UHFFFAOYSA-M 0.000 title 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003257 excitatory amino acid Substances 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 238000002329 infrared spectrum Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 231100000189 neurotoxic Toxicity 0.000 abstract 1
- 230000002887 neurotoxic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
CARACTERIZADA PORQUE EL CONTENIDO DE AGUA ES ENTRE 2,5% A 3,1% EN PESO; ASI COMO POR SU ESPECTRO INFRAROJO Y POR SU PATRON DE DIFRACCION DE RAYOS X . TAMBIEN SE REFIERE AL PROCESO PARA SU PREPARACION QUE COMPRENDE LA HIDROLISIS DEL ESTER DE ALQUILO POR REACCION CON NaOH ACUOSO EN PRESENCIA DE UN ALCOHOL SEGUIDO POR LA ADICION DE AGUA. ESTE COMPUESTO ANTAGONIZA LOS EFECTOS DE LOS AMINOACIDOS EXCITATORIOS SOBRE EL COMPLEJO RECEPTOR N-METIL-D-ASPARTATO (NMDA), POR LO QUE PUEDE SER UTIL EN EL TRATAMIENTO DE PREVENCION DE DANOS NEUROTOXICOS Y ENFERMEDADES NEURODEGENERATIVASCHARACTERIZED BECAUSE THE WATER CONTENT IS BETWEEN 2.5% TO 3.1% BY WEIGHT; AS WELL AS ITS INFRARED SPECTRUM AND ITS X-RAY DIFFACTION PATTERN. IT ALSO REFERS TO THE PROCESS FOR ITS PREPARATION WHICH INCLUDES THE HYDROLYSIS OF THE ALKYL ESTER BY REACTION WITH AQUEOUS NaOH IN THE PRESENCE OF AN ALCOHOL FOLLOWED BY THE ADDITION OF WATER. THIS COMPOUND ANTAGONIZES THE EFFECTS OF EXCITATORY AMINO ACIDS ON THE N-METHYL-D-ASPARTATE RECEPTION COMPLEX (NMDA), SO IT CAN BE USEFUL IN THE TREATMENT OF NEUROTOXIC DAMAGE PREVENTION AND NEURODEGENERATIVE DISEASES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9704498.6A GB9704498D0 (en) | 1997-03-05 | 1997-03-05 | Chemical compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE51399A1 true PE51399A1 (en) | 1999-06-07 |
Family
ID=10808697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998000149A PE51399A1 (en) | 1997-03-05 | 1998-03-03 | HYDRATED CRYSTALLINE FORM OF SODIUM SALT ACID (E) -4,6-DICHLORO-3- (2-OXO-1-FENILPIRROLIDIN-3-ILIDENO-METHYL) -1H-INDOL-2-CARBOXILICO |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0966463A1 (en) |
| JP (1) | JP2001513796A (en) |
| KR (1) | KR20000075907A (en) |
| CN (1) | CN1249750A (en) |
| AP (1) | AP9901637A0 (en) |
| AR (1) | AR011178A1 (en) |
| AU (1) | AU6825198A (en) |
| BG (1) | BG103779A (en) |
| BR (1) | BR9808305A (en) |
| CA (1) | CA2282851A1 (en) |
| CO (1) | CO4940415A1 (en) |
| EA (1) | EA199900710A1 (en) |
| EE (1) | EE9900387A (en) |
| GB (1) | GB9704498D0 (en) |
| HR (1) | HRP980114A2 (en) |
| HU (1) | HUP0002109A2 (en) |
| ID (1) | ID24207A (en) |
| IL (1) | IL131489A0 (en) |
| IS (1) | IS5166A (en) |
| NO (1) | NO994303L (en) |
| NZ (1) | NZ337315A (en) |
| OA (1) | OA11154A (en) |
| PE (1) | PE51399A1 (en) |
| PL (1) | PL335652A1 (en) |
| SK (1) | SK119699A3 (en) |
| TR (1) | TR199902117T2 (en) |
| WO (1) | WO1998039327A1 (en) |
| YU (1) | YU43499A (en) |
| ZA (1) | ZA981791B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9704499D0 (en) * | 1997-03-05 | 1997-04-23 | Glaxo Wellcome Spa | Method of manufacture |
| GB9825988D0 (en) * | 1998-11-27 | 1999-01-20 | Pfizer Ltd | Indole derivatives |
| GB9915231D0 (en) | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| AU2018284335A1 (en) | 2017-06-12 | 2020-01-30 | Glytech Llc. | Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9321221D0 (en) * | 1993-10-14 | 1993-12-01 | Glaxo Spa | Heterocyclic compounds |
-
1997
- 1997-03-05 GB GBGB9704498.6A patent/GB9704498D0/en active Pending
-
1998
- 1998-03-03 NZ NZ337315A patent/NZ337315A/en unknown
- 1998-03-03 JP JP53813598A patent/JP2001513796A/en active Pending
- 1998-03-03 EP EP98913613A patent/EP0966463A1/en not_active Withdrawn
- 1998-03-03 KR KR1019997007987A patent/KR20000075907A/en not_active Withdrawn
- 1998-03-03 YU YU43499A patent/YU43499A/en unknown
- 1998-03-03 ZA ZA9801791A patent/ZA981791B/en unknown
- 1998-03-03 BR BR9808305-8A patent/BR9808305A/en not_active Application Discontinuation
- 1998-03-03 AR ARP980100948A patent/AR011178A1/en unknown
- 1998-03-03 EE EEP199900387A patent/EE9900387A/en unknown
- 1998-03-03 IL IL13148998A patent/IL131489A0/en unknown
- 1998-03-03 PL PL98335652A patent/PL335652A1/en unknown
- 1998-03-03 CA CA002282851A patent/CA2282851A1/en not_active Abandoned
- 1998-03-03 SK SK1196-99A patent/SK119699A3/en unknown
- 1998-03-03 AP APAP/P/1999/001637A patent/AP9901637A0/en unknown
- 1998-03-03 HU HU0002109A patent/HUP0002109A2/en unknown
- 1998-03-03 PE PE1998000149A patent/PE51399A1/en not_active Application Discontinuation
- 1998-03-03 WO PCT/EP1998/001146 patent/WO1998039327A1/en not_active Ceased
- 1998-03-03 TR TR1999/02117T patent/TR199902117T2/en unknown
- 1998-03-03 ID IDW990976A patent/ID24207A/en unknown
- 1998-03-03 CO CO98011404A patent/CO4940415A1/en unknown
- 1998-03-03 CN CN98803053A patent/CN1249750A/en active Pending
- 1998-03-03 AU AU68251/98A patent/AU6825198A/en not_active Abandoned
- 1998-03-03 EA EA199900710A patent/EA199900710A1/en unknown
- 1998-03-04 HR HR9704498.6A patent/HRP980114A2/en not_active Application Discontinuation
-
1999
- 1999-08-27 IS IS5166A patent/IS5166A/en unknown
- 1999-09-02 OA OA9900201A patent/OA11154A/en unknown
- 1999-09-03 NO NO994303A patent/NO994303L/en not_active Application Discontinuation
- 1999-10-04 BG BG103779A patent/BG103779A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20000075907A (en) | 2000-12-26 |
| NO994303L (en) | 1999-11-03 |
| TR199902117T2 (en) | 2000-03-21 |
| EE9900387A (en) | 2000-04-17 |
| YU43499A (en) | 2000-12-28 |
| NO994303D0 (en) | 1999-09-03 |
| AR011178A1 (en) | 2000-08-02 |
| SK119699A3 (en) | 2000-05-16 |
| JP2001513796A (en) | 2001-09-04 |
| PL335652A1 (en) | 2000-05-08 |
| ZA981791B (en) | 1999-09-03 |
| IL131489A0 (en) | 2001-01-28 |
| WO1998039327A1 (en) | 1998-09-11 |
| AP9901637A0 (en) | 1999-09-30 |
| CO4940415A1 (en) | 2000-07-24 |
| CA2282851A1 (en) | 1998-09-11 |
| HUP0002109A2 (en) | 2001-04-28 |
| IS5166A (en) | 1999-08-27 |
| BR9808305A (en) | 2000-05-16 |
| CN1249750A (en) | 2000-04-05 |
| ID24207A (en) | 2000-07-13 |
| NZ337315A (en) | 2001-02-23 |
| OA11154A (en) | 2003-04-16 |
| GB9704498D0 (en) | 1997-04-23 |
| HRP980114A2 (en) | 1998-12-31 |
| AU6825198A (en) | 1998-09-22 |
| EA199900710A1 (en) | 2000-04-24 |
| BG103779A (en) | 2000-06-30 |
| EP0966463A1 (en) | 1999-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY24179A1 (en) | PROCEDURE FOR OBTAINING TROMETAMINE SALT FROM (+) - (S) -2- (3-BENZOYLPHENIL) -PROPIONIC ACID | |
| ES8402292A1 (en) | PROCEDURE FOR THE PREPARATION OF N-ALCOHYL-NORESCOPINS. | |
| MX9604882A (en) | Process for the preparation of dihaloazolopyrimidines. | |
| ES8207498A1 (en) | A PROCEDURE FOR PREPARING AMINO CYCLE-PENTAN-ALKENOIC ACIDS AND ESTERS | |
| AR031108A1 (en) | A METHOD FOR IMPROVING THE ACTIVITY OF AN ALUMINUM OR ALUMINUM / CIRCONIUM SALT CONTAINING SMALL AND LARGE ALUMINUM SPECIES, SALES SO OBTAINED AND ANTI-TRANSPIRING AND / OR DEODORANT PRODUCTS PREPARED WITH SUCH IMPROVED SALTS | |
| ES8604544A1 (en) | PROCEDURE FOR PREPARING NEW DERIVATIVES OF PHENI-LACETIC ACIDS | |
| ES2143670T3 (en) | FORMATION OF STABLE AQUEOUS SOLUTIONS OF STANTIOUS COMPOUNDS. | |
| PE51399A1 (en) | HYDRATED CRYSTALLINE FORM OF SODIUM SALT ACID (E) -4,6-DICHLORO-3- (2-OXO-1-FENILPIRROLIDIN-3-ILIDENO-METHYL) -1H-INDOL-2-CARBOXILICO | |
| ES2166093T3 (en) | PROCEDURE FOR THE PREPARATION OF PIRIMIDINE COMPOUNDS. | |
| AR247386A1 (en) | Ethers of 1-benzyl-3-hydroxymethyl-indazole with aliphatic 2-hydroxyacids | |
| JPS5538345A (en) | Novel aminoglycoside derivative | |
| ES2148475T3 (en) | PROCEDURE FOR DEVELOPING SOLID FORMULATIONS CONTAINING SURFACE AGENTS OF AMINE OXIDES. | |
| PE20030389A1 (en) | PROCEDURE FOR THE PREPARATION OF 4,4'-DICETO-ß-CAROTENE DERIVATIVES | |
| ATE323602T1 (en) | IMAGE RECORDING MATERIAL AND PLATE PRINTING PLATE WITH THIS IMAGE RECORDING MATERIAL | |
| ES2135040T3 (en) | SOLID COMPOSITIONS CONTAINING SALTS OF AMINE OXIDE-MALEIC ACID. | |
| ES8705356A1 (en) | PROCEDURE FOR THE PREPARATION OF NAVYL-ANALOGUE COMPOUNDS OF MEVALONOLACTONE AND ITS DERIVATIVES | |
| DE3466692D1 (en) | Derivatives of 5h-û1¨benzopyrano-û2,3-d¨-pyrimidines, process for their preparation and medicines containing them, useful against gastral and duodenal lesions of the mucosa | |
| PT84819B (en) | PROCESS FOR THE PREPARATION OF COMPOUNDS 2-PYRIDYL-PENEM | |
| ES535694A0 (en) | PROCEDURE FOR THE MANUFACTURE OF BENZOIC ACID DERIVATIVES WITH ANTIMICROBIAL ACTIVITY | |
| CO4980899A1 (en) | PROCESS FOR THE SYNTHESIS OF INTERMEDIATE CHLOROPURINE COMPOUNDS | |
| TR199800860T2 (en) | Production of a clavulanic acid salt. | |
| DE3571970D1 (en) | Process for the preparation of alcoxymethylene compounds of esters of acetic acid and substituted acetic acid | |
| PE20000271A1 (en) | PHARMACEUTICAL COMPOSITION OF (1S, 4R) -CIS-4- [2-AMINO-6- (CYCLOPROPYLAMINE) -9H-PURIN-9-IL] -2-CYCLOPENTENE-1-METHANOL | |
| ES8202806A1 (en) | PROCEDURE FOR THE PREPARATION OF NEW AMIDES OF CARBOXYL ACIDS | |
| ES2169206T3 (en) | PROCEDURE FOR THE PREPARATION OF ACID 1,2,3,4-TETRAHIDRO-2-ISOQUINOLINACARBOXILICO OPTICALLY PURE AND ITS DERIVATIVES. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |